ABBV - AbbVie Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
82.9100
-1.3600 (-1.61%)
As of 10:49AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close84.2700
Open82.5800
Bid82.8500 x 800
Ask82.9100 x 1300
Day's Range81.5000 - 84.5900
52 Week Range81.5000 - 125.8600
Volume2,022,388
Avg. Volume5,376,483
Market Cap125.548B
Beta (3Y Monthly)1.47
PE Ratio (TTM)20.58
EPS (TTM)4.0290
Earnings DateNov 2, 2018
Forward Dividend & Yield3.84 (4.56%)
Ex-Dividend Date2018-10-12
1y Target Est108.61
Trade prices are not sourced from all markets
  • Reuters3 minutes ago

    AbbVie rheumatoid arthritis drug succeeds in late stage trial

    AbbVie Inc on Tuesday said its experimental rheumatoid arthritis (RA) treatment showed significant improvement in physical function, pain and quality of life compared with the commonly prescribed generic drug methotrexate in a late stage clinical trial. The U.S. drugmaker hopes the drug, upadacitinib, can help replace lost revenue from its top-selling RA treatment Humira when it starts to face biosimilar competition in the United States in 2023. AbbVie said it will file applications this years seeking regulatory approval for the medicine.

  • Reuters35 minutes ago

    AbbVie rheumatoid arthritis drug succeeds in late stage trial

    AbbVie Inc on Tuesday said its experimental rheumatoid arthritis (RA) treatment showed significant improvement in physical function, pain and quality of life compared with the commonly prescribed generic drug methotrexate in a late stage clinical trial. The U.S. drugmaker hopes the drug, upadacitinib, can help replace lost revenue from its top-selling RA treatment Humira when it starts to face biosimilar competition in the United States in 2023. AbbVie said it will file applications this years seeking regulatory approval for the medicine.

  • PR Newswire2 hours ago

    AbbVie's Upadacitinib Shows Significant Improvements in Physical Function, Pain and Quality of Life as a Monotherapy in Patients with Rheumatoid Arthritis in Phase 3 Patient-Reported Outcomes Data

    - Upadacitinib monotherapy showed improvements in physical function, a measure that assesses patients' ability to perform daily activities and level of disability, versus methotrexate at week 14 - Upadacitinib-treated ...

  • ACCESSWIRE3 hours ago

    Today's Research Reports on Trending Tickers: AbbVie and Endo International

    NEW YORK, NY / ACCESSWIRE / October 23, 2018 / Major U.S. equities finished lower Monday on a combination of rising interest rates and global growth concerns. Investors await a flood of corporate earnings ...

  • ACCESSWIRE15 hours ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline - ABBV

    NEW YORK, NY / ACCESSWIRE / October 22, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against AbbVie Inc. ("AbbVie" or the "Company") (ABBV) and certain of its officers. The class action, filed in United States District Court, Northern District of Illinois, and index under 18-cv-06790, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired the publicly traded securities of AbbVie between October 25, 2013 and September 18, 2018, both dates inclusive (the "Class Period").

  • PR Newswire17 hours ago

    Positive Phase 2b Data for AbbVie's Upadacitinib Show Significant Induction of Clinical Remission and Response in Patients with Ulcerative Colitis

    - In U-ACHIEVE, upadacitinib (15/30/45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all ranked secondary endpoints, including endoscopic improvement, clinical ...

  • Investing.com21 hours ago

    AbbVie Falls 3%

    Investing.com - AbbVie (NYSE:ABBV) fell by 3.10% to trade at $85.240 by 10:19 (14:19 GMT) on Monday on the NYSE exchange.

  • 3 Dividend Stocks That Pay You More Than Coca-Cola Does
    Motley Fool2 days ago

    3 Dividend Stocks That Pay You More Than Coca-Cola Does

    Coke has treated investors well for decades, but there are better opportunities today.

  • ACCESSWIRE4 days ago

    Investor Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / October 19, 2018 /The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. ("AbbVie" or "the Company") (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between October 25, 2013 and September 18, 2018, inclusive (the "Class Period"), are encouraged to contact the firm before November 20, 2018.

  • GlobeNewswire4 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline – ABBV

    Pomerantz LLP announces that a class action lawsuit has been filed against AbbVie Inc. (“AbbVie” or the “Company”) (NYSE:  ABBV) and certain of its officers.   The class action, filed in United States District Court, Northern District of Illinois, and index under 18-cv-06790, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired the publicly traded securities of AbbVie between October 25, 2013 and September 18, 2018, both dates inclusive (the “Class Period”). Plaintiff seeks to recover compensable damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

  • GlobeNewswire4 days ago

    ABBV NOTICE ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against AbbVie Inc.; Important Deadline – ABBV

    NEW YORK, Oct. 19, 2018 -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of AbbVie.

  • Reuters4 days ago

    AbbVie CFO Chase to retire by mid-year 2019

    Michael, 48, will report to Chase, who as of Friday becomes executive vice president of finance and administration. The move came as a surprise and raises questions as the company faces new competition for its top drug, the rheumatoid arthritis treatment Humira, Credit Suisse analyst Vamil Divan wrote in a research note. AbbVie said in a filing with the U.S. Securities and Exchange Commission that Chase, who was 50 at the time AbbVie filed its annual report in February, had informed it that he planned to retire from the company.

  • Reuters4 days ago

    AbbVie names Robert Michael chief financial officer

    AbbVie Inc on Friday appointed Robert Michael as its chief financial officer, replacing William Chase, who will retire in mid-2019. The drugmaker said http://www.sec.gov/Archives/edgar/data/1551152/000110465918062867/0001104659-18-062867-index ...

  • MarketWatch4 days ago

    AbbVie CFO Bill Chase to retire

    AbbVie Inc. disclosed Friday that Chief Financial Officer William "Bill" Chase plans to retire in mid-2019, and will be succeeded as CFO by Robert Michael effective Friday. The stock slipped 0.7% in morning trade. Chase has been appointed executive vice president of finance and administration, also effective Friday. Michael, how has been the biopharmaceutical company's controller since March 1, 2017, will continue to report to Chase. Brian Durkin, who has been vice president of internal audit, was appointed controller. AbbVie's stock has lost 7.7% year to date, while the S&P 500 has slipped 1.0%.

  • What to Expect from Thermo Fisher’s Third-Quarter Earnings
    Market Realist4 days ago

    What to Expect from Thermo Fisher’s Third-Quarter Earnings

    Thermo Fisher Scientific (TMO), a leading life sciences company, is scheduled to release its third-quarter earnings on October 24. Wall Street analysts expect the adjusted EPS to be $2.55 on revenues of $5.7 billion during the third quarter.

  • ACCESSWIRE5 days ago

    Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / October 18, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. ("AbbVie" or "the Company") (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between October 25, 2013 and September 18, 2018, inclusive (the "Class Period"), are encouraged to contact the firm before November 20, 2018.

  • Investing.com5 days ago

    AbbVie Falls 3%

    Investing.com - AbbVie (NYSE:ABBV) fell by 3.06% to trade at $89.450 by 13:25 (17:25 GMT) on Thursday on the NYSE exchange.

  • GlobeNewswire5 days ago

    Hagens Berman Reminds Investors in AbbVie Inc. (NYSE: ABBV) of the Firm’s Ongoing Investigation and the November 20, 2018 Securities Class Action Lead Plaintiff Deadline

    SAN FRANCISCO, Oct. 18, 2018 -- Hagens Berman Sobol Shapiro LLP reminds investors in AbbVie Inc. (NYSE: ABBV) of the November 20, 2018 Lead Plaintiff deadline in the pending.

  • FDA Accepts Application for AbbVie's Imbruvica in Specific Blood Cancers
    GuruFocus.com5 days ago

    FDA Accepts Application for AbbVie's Imbruvica in Specific Blood Cancers

    AbbVie (ABBV) has seen its marketing application for its drug Imbruvica combined with Roche (RO.SW)'s Gazyva, accepted by the U.S. Food and Drug Administration for a priority review as treatment for adult patients affected with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). If the U.S. agency approves the marketing application, the combined therapy of AbbVie's Imbruvica and Roche's Gazyva will be the first treatment given for lymphocytic leukaemia or small lymphocytic lymphoma.

  • GlobeNewswire5 days ago

    SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline – November 20, 2018

    Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AbbVie securities between October 25, 2013 and September 18, 2018, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/abbv. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

  • Reuters5 days ago

    AbbVie settles Humira biosimilar dispute with Fresenius Kabi

    In the European Union, Fresenius Kabi can launch its biosimilar upon approval from the European Medicines Agency, while the license period in the United States will begin on Sept. 30, 2023, AbbVie said. Fresenius Kabi will pay royalties to AbbVie for licensing its patents for Humira, which is used to treat rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis.

  • Reuters5 days ago

    AbbVie settles Humira biosimilar dispute with Fresenius Kabi

    U.S. drugmaker AbbVie Inc said on Thursday it has settled a patent dispute regarding its Humira biosimilar with Fresenius Kabi Oncology Ltd and will grant the Germany-based company non-exclusive marketing rights for the drug. In the European Union, Fresenius Kabi can launch its biosimilar upon approval from the European Medicines Agency, while the license period in the United States will begin on Sept. 30, 2023, AbbVie said.

  • PR Newswire5 days ago

    AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Fresenius Kabi

    NORTH CHICAGO, Ill., Oct. 18, 2018 /PRNewswire/ -- AbbVie (ABBV) announced today global resolution of all intellectual property-related litigation with Fresenius Kabi over its proposed biosimilar adalimumab product. In the U.S., the Fresenius Kabi license period will begin on September 30, 2023 and will not be accelerated by the entry of companies who have already taken a license.

  • Waltham's Morphic Therapeutic inks $100M deal with AbbVie
    American City Business Journals5 days ago

    Waltham's Morphic Therapeutic inks $100M deal with AbbVie

    A preclinical Waltham biotech company is hoping to launch their first clinical trial of a fibrosis treatment next year after signing a $100 million collaboration agreement with AbbVie this week.

  • PR Newswire5 days ago

    AbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases

    NORTH CHICAGO, Ill. and WALTHAM, Mass., Oct. 18, 2018 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, and Morphic Therapeutic, a biotechnology company developing oral integrin therapies, announced today that the companies have entered into a research and development collaboration designed to advance a number of Morphic's oral integrin therapeutics for fibrosis-related indications. Morphic Therapeutic has developed a unique platform for designing integrin oral inhibitors to block TGF-β activation, thought to be a key approach to halt or reverse fibrosis, in a tissue-specific manner. The platform was developed through foundational collaborations with Morphic scientific founder Tim Springer and Schrödinger, Inc.